Clinical Impact of Tetracyclines And/or Proton Pump Inhibitors on the Efficacy of Epidermal Growth Factor Receptor Inhibitors in Non-small Cell Lung Cancer: a Retrospective Cohort Study

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2023 Feb 14

PMID 36782147

Authors

Hui-Hsia Hsieh

Tien-Yuan Wu

Chi-Hua Chen

Yu-Hung Kuo

Mann-Jen Hour

Affiliations

Soon will be listed here.

Abstract

Background: This retrospective cohort study examined the impact of tetracyclines (TCs) and proton pump inhibitors (PPIs) alone or in combination on the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in patients with non-small cell lung cancer (NSCLC).

Methods: Patients with NSCLC treated with gefitinib or erlotinib for at least 1 week between January 2009 and October 2021 were enrolled and divided into four groups based on the presence/absence of TC and/or PPI in the therapeutic regimen: TC-/PPI-, TC + /PPI-, TC-/PPI + , TC + /PPI + . Progression-free survival (PFS) and overall survival (OS) were the primary and secondary endpoints, respectively.

Results: The estimated median PFS and OS of 347 included patients with NSCLC were 8.57 (95% confidence interval [CI]: 7.66-9.48) months and 13.10 (95% CI: 11.03-15.17) months, respectively. Co-administration of EGFR-TKIs with PPIs decreased the PFS and OS, while that with TCs improved the PFS and OS. However, the concomitant use of EGFR-TKIs, TCs, and PPIs yielded survival rates similar to that of EGFR-TKI therapy alone.

Conclusions: The administration of EGFR-TKIs with other drugs poses a challenge in managing patients with NSCLC. Therefore, reassessing the indications and necessity of TC or PPI therapy is essential for patients receiving erlotinib or gefitinib. The benefits and risks of possible discontinuation due to the clinical relevance of this interaction should be considered.

Citing Articles

Drug-Drug Interactions in Nosocomial Infections: An Updated Review for Clinicians.

Hincu S, Apetroaei M, Stefan G, Faca A, Arsene A, Mahler B Pharmaceutics. 2024; 16(9).

PMID: 39339174 PMC: 11434876. DOI: 10.3390/pharmaceutics16091137.

Gut resistome of NSCLC patients treated with immunotherapy.

Iwan E, Grenda A, Bomba A, Bielinska K, Wasyl D, Kieszko R Front Genet. 2024; 15:1378900.

PMID: 39170692 PMC: 11335565. DOI: 10.3389/fgene.2024.1378900.

The Complex Interaction between Proton Pump Inhibitors and Cancer Treatment.

Chen H, Kondo M, Horita N, Takahashi K, Kaneko T Cancers (Basel). 2023; 15(22).

PMID: 38001605 PMC: 10670233. DOI: 10.3390/cancers15225346.

Survival Outcomes of Calcium Channel Blocker Therapy in Patients With Non-Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Inhibitors: A Retrospective Study.

Hsieh H, Wu T, Chen C, Kuo Y, Hour M Integr Cancer Ther. 2023; 22:15347354231178903.

PMID: 37291860 PMC: 10262673. DOI: 10.1177/15347354231178903.

References

Melosky B, Anderson H, Burkes R, Chu Q, Hao D, Ho V . Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer. J Clin Oncol. 2015; 34(8):810-5. DOI: 10.1200/JCO.2015.62.3918. View

Uchiyama A, Silva P, Lopes M, Yen C, Ricardo E, Mutao T . Proton Pump Inhibitors and Oncologic Treatment Efficacy: A Practical Review of the Literature for Oncologists. Curr Oncol. 2021; 28(1):783-799. PMC: 7985775. DOI: 10.3390/curroncol28010076. View

Petrelli F, Borgonovo K, Cabiddu M, Lonati V, Barni S . Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials. Lung Cancer. 2012; 78(1):8-15. DOI: 10.1016/j.lungcan.2012.06.009. View

Grahnen A, Olsson B, Johansson G, Eckernas S . Doxycycline carrageenate--an improved formulation providing more reliable absorption and plasma concentrations at high gastric pH than doxycycline monohydrate. Eur J Clin Pharmacol. 1994; 46(2):143-6. DOI: 10.1007/BF00199878. View

Yasumuro O, Uchida S, Kashiwagura Y, Suzuki A, Tanaka S, Inui N . Changes in gefitinib, erlotinib and osimertinib pharmacokinetics under various gastric pH levels following oral administration of omeprazole and vonoprazan in rats. Xenobiotica. 2017; 48(11):1106-1112. DOI: 10.1080/00498254.2017.1396379. View

Vazquez S, Casal J, Afonso Afonso F, Firvida J, Santome L, Baron F . EGFR testing and clinical management of advanced NSCLC: a Galician Lung Cancer Group study (GGCP 048-10). Cancer Manag Res. 2016; 8:11-20. PMC: 4745839. DOI: 10.2147/CMAR.S85173. View

Siegel R, Miller K, Fuchs H, Jemal A . Cancer Statistics, 2021. CA Cancer J Clin. 2021; 71(1):7-33. DOI: 10.3322/caac.21654. View

Peters S, Zimmermann S, Adjei A . Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions. Cancer Treat Rev. 2014; 40(8):917-26. DOI: 10.1016/j.ctrv.2014.06.010. View

Bogardus J, Blackwood Jr R . Solubility of doxycycline in aqueous solution. J Pharm Sci. 1979; 68(2):188-94. DOI: 10.1002/jps.2600680218. View

10.

Sachs G, Shin J, Howden C . Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther. 2006; 23 Suppl 2:2-8. DOI: 10.1111/j.1365-2036.2006.02943.x. View

11.

Lacouture M, Sibaud V, Gerber P, van den Hurk C, Fernandez-Penas P, Santini D . Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines. Ann Oncol. 2020; 32(2):157-170. DOI: 10.1016/j.annonc.2020.11.005. View

12.

Nieves Sedano M, Caro Teller J, Garcia Munoz C, Fernandez Redondo D, Aix S, Menendez Orenga M . Clinical impact of gastric acid suppressing medication on the effectiveness of tyrosine kinase inhibitors in lung cancer patients. J BUON. 2018; 23(3):647-653. View

13.

Shah R, Shah D . Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Oncology. Drug Saf. 2019; 42(2):181-198. DOI: 10.1007/s40264-018-0772-x. View

14.

Tougeron D, Emambux S, Favot L, Lecomte T, Wierzbicka-Hainaut E, Samimi M . Skin inflammatory response and efficacy of anti-epidermal growth factor receptor therapy in metastatic colorectal cancer (CUTACETUX). Oncoimmunology. 2020; 9(1):1848058. PMC: 7714491. DOI: 10.1080/2162402X.2020.1848058. View

15.

Smelick G, Heffron T, Chu L, Dean B, West D, DuVall S . Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development. Mol Pharm. 2013; 10(11):4055-62. DOI: 10.1021/mp400403s. View

16.

Gao G, Ren S, Li A, Xu J, Xu Q, Su C . Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials. Int J Cancer. 2011; 131(5):E822-9. DOI: 10.1002/ijc.27396. View

17.

Alanen V, Iivanainen S, Arffman M, Koivunen J . Tetracyclines increase the survival of NSCLC patients treated with EGFR TKIs: a retrospective nationwide registry study. ESMO Open. 2020; 5(5):e000864. PMC: 7580060. DOI: 10.1136/esmoopen-2020-000864. View

18.

Ogawa R, Echizen H . Clinically significant drug interactions with antacids: an update. Drugs. 2011; 71(14):1839-64. DOI: 10.2165/11593990-000000000-00000. View

19.

Li J, Nickens D, Wilner K, Tan W . Evaluation of the Effect of Proton Pump Inhibitors on the Efficacy of Dacomitinib and Gefitinib in Patients with Advanced Non-Small Cell Lung Cancer and EGFR-Activating Mutations. Oncol Ther. 2021; 9(2):525-539. PMC: 8593125. DOI: 10.1007/s40487-021-00156-2. View

20.

Chu M, Ghosh S, Chambers C, Basappa N, Butts C, Chu Q . Gastric Acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer. Clin Lung Cancer. 2014; 16(1):33-9. DOI: 10.1016/j.cllc.2014.07.005. View